Comparison of a Novel ETA Receptor Antagonist and Phosphoramidon in Renal Ischemia

Infusion (0.46 µmol/kg/min) of the endothelin (ET)-converting-enzyme inhibitor, phosphoramidon (P), protected function and structure after 30 min renal ischemia in rats more than treatment (5 µmol/kg/